Glenmark To Launch Generic Adderall Tablets In US

Glenmark Pharmaceuticals Inc., a subsidiary of Glenmark Pharmaceutical, will launch its generic version of Adderall tablets in the US market in May, the company said in an exchange filing on Wednesday.

The tablets, used to treat attention deficit hyperactivity disorder, are therapeutically equivalent to those of Teva Women’s Health Inc. and will be available in five strengths. Glenmark said the US market for Adderall tablets was worth around $421 million for the 12 months ended February.

The company added that the launch comes at a time when the US is facing a shortage of these tablets, and the move is expected to help meet the existing demand